Detection of abnormal maturation patterns is one of the most commonly used phenotypic criteria to identify B-cell leukemic cells after chemotherapy or SCT. We report two patients who underwent allo-cord blood SCT following the same protocol, and presented immature lymphoid cells in a BM smear with an abnormal maturation pattern shortly after, which led to suspicion of relapse. The transplant protocol included a conditioning regimen with thiotepa 10 mg/kg, fludarabine 150 mg/m 2 and i.v. busulfan 9.6 mg/ kg. GVHD prophylaxis included anti-thymocyte globulin 6 mg/kg, CYA and mycophenolate mofetil.
1
Patient 1 was a 34-year-old woman with CML in first chronic phase. At diagnosis she presented with lymphoid blast crisis (CD10 þ , CD19 þ , CD20À, CD22À, CD34low þ , CD123 þ , DR þ , CD79a þ , CD3À, TdT þ , blasts) and was treated with dasatinib 140 mg/day, achieving complete molecular remission. A single cord blood unit (5/6 Ag-matched, female) was infused at day 0 (1.6 Â 10 5 /kg of CD34 þ cells, 3.7 Â 10 7 /kg of total nucleated cells). The early post-SCT period was uneventful and a short-tandem repeat chimerism study on a BM aspirate performed on day þ 15 showed full-donor chimerism. No cytological or immunophenotypic evaluation of baseline disease was possible because of the low number of cells in the sample. No Bcr-Abl transcript was detected using RT-PCR. Complete hematopoietic recovery was achieved on day þ 31. On day þ 38, the patient presented EBV reactivation by means of RT-PCR (7500 copies/mL) and four doses of weekly rituximab (375 mg/m 2 ) were administered. At day þ 65, a BM aspirate was performed, revealing low overall cellularity with o5% mature lymphocytes and 9% morphologically atypical blast cells with an abnormal maturation pattern similar to that at diagnosis. With the suspicion of an early relapse, dasatinib was immediately resumed. Three days later, the results of RT-PCR showed o0.1% of Bcr-Abl transcripts; conventional cytogenetics revealed normal karyotype, and chimerism analyses showed complete donor-derived hematopoiesis. The patient was now considered to be in remission and dasatinib was discontinued. Six weeks later, a new BM aspirate was performed. Normal lymphocyte count rose up to 15%, and 5% of lymphoblasts were found. Abnormal maturation pattern was detected in only 2% of the cells (Figure 1) . The patient continued in molecular remission. Now, 3 years after SCT, the patient is still in molecular response and without any evidence of GVHD.
Patient 2 was a 24-year-old woman diagnosed with B-cell ALL with normal karyotype and no molecular markers. The patient achieved first CR after standard therapy, 2 and was considered a candidate for SCT because of persistent minimal residual disease by flow cytometry after consolidation therapy (CD10 þ , CD19 þ , CD20À, CD34low þ , CD45 þ , TdT low þ ). She received a single cord blood unit (6/6 Ag-matched, male) at day 0 (1.6 Â 10 /L) at day þ 20 and was discharged at day þ 27. A BM smear at day þ 48 showed 8% lymphoid blasts with an abnormal phenotype (CD10 þ , CD19 þ , CD20À, CD34 þ , CD45 þ , TdT low þ ) similar to diagnosis. As she had full-donor chimerism and had no other analytical or clinical signs of relapse, no therapeutic intervention was performed. A second BM aspirate was performed 3 weeks later showing only 4% immature cells with a normal expression pattern, except for abrogation of CD20. The patient is now 20 months after SCT and continues in CR without evidence of GVHD.
In recent years, the use of unrelated cord blood units for allo-SCT has increased markedly. 3 Patients undergoing such transplants may present specific hematological and immune reconstitution patterns compared with those receiving BM or PB. For instance, earlier and more intense B-cell reconstitution after cord blood transplantation (CBT) compared with BM or PB allo-SCT has been recognized. 4 Detection of immature CD34 þ B cells has been identified as a normal phenomenon in murine models after CBT, with secondary reconstitution occurring exclusively in the CD34 þ population. 5 Furthermore, heterogeneous B-cell lymphoproliferation, with complex morphological and phenotypical features, has been recently described in patients with AML after allo-cord blood SCT. 6 Direct observation of BM smear and flow cytometry are the two fastest techniques for the detection of relapse after therapy in patients with leukemia. Moreover, persistence of minimal residual disease measured by flow cytometry after SCT has been associated with lower disease-free survival in ALL patients. 7 Hence, these patients might be candidates for specific therapeutic approaches like reduction of immunosuppressive therapy or donor lymphocyte infusions.
One of the most frequent aberrant phenotypes in CML lymphoid blastic phase is CD10 þ , CD19 þ , CD20À, CD34 þ , CD79a þ and TdT þ . In these patients, CD20 expression appears to be relatively rare (around 15%).
As patient 1 presented this same phenotype at blastic phase and immature blast cells were observed in the BM smear after transplant, an early relapse after allo-cord blood SCT was suspected. Fortunately, cytogenetics and molecular detection of Bcr-Abl transcript are useful techniques for detection of minimal residual disease after transplantation in CML and contributed to confirming remission in our patient. However, in ALL patients without cytogenetic or molecular abnormalities (as in patient 2), flow cytometry and BM smear observation might be critical for determining remission of baseline disease.
EBV reactivation is frequent after CBT with reported incidences ranging from 1 to 25%. 9 The bad prognosis of EBV-related post-transplant lymphoproliferative disorder, especially monomorphic variants, has prompted adoption of measures. A pre-emptive strategy using EBV-DNA viral load monitoritzation and an early intervention (tapering of immunosuppression and/or the use of rituximab) in case of elevation of viral load has been adopted by most transplant centers. The rationale behind the use of rituximab is based on the fact that B cells are the preferred sites for the intracellular stages of the replication cycle of EBV. CD20 is expressed in all stages of B-cell development, except for pro-B and plasma cells. Consequently, rituximab may induce abnormal B-cell antigen expression, which may persist for months. Owing to the previously mentioned high number of immature B cells, shortly after CBT, this CD20 abrogation might be seen in immature cells, mimicking pathological phenotypes in progenitor B-cell malignancies. However, in contrast with others' findings, 10 our patients seemed to experience faster B-cell reconstitution, as a significant proportion of normal B cells were observed a few weeks after finishing rituximab treatment.
In conclusion, cytological and flow cytometry findings after CBT should be put together with cytogenetics and PCR analysis before considering therapeutic interventions in patients with progenitor B-cell malignancies treated with rituximab and other monoclonal antibodies. This may be especially relevant in ALL with normal cytogenetics and no molecular markers, as BM smear observation and flow cytometry might be the only techniques available for minimal residual disease detection.
